{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-011805","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.793758+00:00","generated_at":"2026-06-17T03:44:10.436881+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"high","headline":"Anebulo furnishes Part B final data charts for ANEB-001 Phase 2 trial, consistent with prior results","bullets":["Exhibit 99.1 contains graphical charts of Part B final data from Phase 2 trial of ANEB-001 for acute cannabinoid intoxication.","Data shown is consistent with results reported in the March 28, 2023 Form 8-K.","Trial was randomized, double-blind, placebo-controlled in healthy volunteers challenged with oral delta-9-THC.","No new clinical findings or updated guidance are provided in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-011805","json":"https://secwatch.observer/filing/0001493152-23-011805.json","markdown":"https://secwatch.observer/filing/0001493152-23-011805.md","text":"https://secwatch.observer/filing/0001493152-23-011805.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223011805/0001493152-23-011805-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000149315223011805/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:44:10.436881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}